Molecular Characterization of the 50- and 57-kDa Subunits of the Bovine Vacuolar Proton Pump*

Zhiming Zhou, Sheng-Bin Peng, Bill P. Crider, Clive SlaughterDagger , Xiao-Song Xie, and Dennis K. Stone§

From the Division of Molecular Transport, Department of Internal Medicine, and the Dagger  Howard Hughes Medical Institute, University of Texas Southwestern Medical Center, Dallas, Texas 75235

    ABSTRACT
Top
Abstract
Introduction
Procedures
Results
Discussion
References

The vacuolar type proton-translocating ATPase of clathrin-coated vesicles is composed of two large domains: an extramembranous catalytic sector and a transmembranous proton channel. In addition, two polypeptides of 50 and 57 kDa have been found to co-purify with the pump. These proteins, termed SFD (sub-fifty-eight-kDa dimer) activate ATPase activity of the enzyme and couple ATPase activity to proton flow (Xie, X.-S., Crider, B.P., Ma, Y.-M., and Stone, D. K. (1994) J. Biol. Chem. 269, 28509-25815). It has also been reported that the clathrin-coated vesicle proton pump contains AP50, a 50-kDa component of the AP-2 complex responsible for the assembly of clathrin-coated pits, and that AP50 is essential for function of the proton pump (Liu, Q., Feng, Y., and Forgac, M. (1994) J. Biol. Chem. 269, 31592-31597). We demonstrate through the use of anti-AP50 antibody, identical to that of the latter study, that hydroxylapatite chromatography removes AP50 from impure proton pump preparations and that purified proton pump, devoid of AP50, is fully functional.

To determine the true molecular identity of SFD, both the 50- and 57-kDa polypeptides were directly sequenced. A polymerase chain reaction-based strategy was used to screen a bovine brain cDNA library, yielding independent full-length clones (SFD-4A and SFD-21); these were identical in their open reading frames and encoded a protein with a predicted mass of 54,187 Da. The SFD-21 clone was then used in a reverse transcription-polymerase chain reaction-based strategy to isolate a related, but distinct, transcript present in bovine brain mRNA. The nucleotide and predicted amino acid sequences of this isolate are identical to SFD-21 except that the isolate contains a 54-base pair insert in the open reading frame, resulting in a protein with a predicted mass of 55,933 Da. Both clones had 16% identity to VMA13 of Saccharomyces cerevisiae. No sequence homology between the SFD clones and AP50 was detectable. Anti-peptide antibodies were generated against an epitope common to the two proteins and to the unique 18-amino acid insert of the larger protein. The former reacted with both components of native SFD, whereas the latter reacted only with the 57-kDa component. We term the 57- and 50-kDa polypeptides SFDalpha and SFDbeta , respectively.

    INTRODUCTION
Top
Abstract
Introduction
Procedures
Results
Discussion
References

Vacuolar, or V-type, proton translocating ATPases are found in diverse eukaryotic endomembrane compartments and plasma membranes of epithelia, macrophages, and specialized polarized cells. Their functional roles reflect this broad distribution and range from processing receptor-ligand complexes in endosomes to osteoclast-mediated bone dissolution (1-3).

V-type proton pumps are complex hetero-oligomers with peripheral and intramembranous domains. Preparations of the proton pump of clathrin-coated vesicles contain at least nine proteins of 116, 70, 58, 57, 50, 40, 39, 34, and 33 kDa, as well as four smaller polypeptides with apparent molecular masses of 10-17 kDa (4-7). This polypeptide composition is similar to that of most V-type pumps, reflecting intense phylogenetic conservation (8-12). Functional domains of the coated vesicle proton pump include VB,1 a proton channel that is probably composed of the 116-, 39-, and 17-kDa components (5), and VC, the catalytic sector of the complex consisting of a set of polypeptides of 70, 58, 40, 34, 33, 15, 14, and 10 kDa (6). Separation of VC from the holoenzyme results in marked changes in enzyme activity; although native enzyme hydrolyzes Mg-ATP at a rate 3-fold higher than Ca-ATP, isolated VC can hydrolyze ATP in the presence of Ca2+, but not Mg2+, and cannot support ATP-driven, vectorial proton movement (7). Recently, we reassembled purified VB and VC to yield a complex with Mg-ATPase and proton pumping activities similar to those of native enzyme. Essential to this reconstitution was a heretofore unrecognized 50-57-kDa polypeptide heterodimer, which we termed SFD, for sub-fifty-eight-kDa dimer (6).

Others recently reported that the 50-kDa subunit of the AP-2 clathrin assembly complex is present in their preparation of the clathrin-coated vesicle proton pump and that AP50 might function as a kinase, catalyzing autophosphorylation as well as phosphorylation of the 58-kDa subunit of the pump (13). Subsequently, it was reported that AP50 was essential for the function and assembly of the clathrin-coated vesicle proton pump (14). Although such an interaction could explain the basis whereby endomembrane acidification is regulated by an organellar specific mechanism, these reports are not easily reconciled with the prior demonstrations that AP-2 (and its component, AP50) is found only in plasma membrane-associated clathrin-coated pits and vesicles (15, 16) and that clathrin-coated vesicles associated with the plasma membrane cannot acidify their interiors (17, 18).2

To investigate this point, and to identify the 50- and 57-kDa polypeptides of SFD and their role(s) in pump function, we studied the possible relationship of the 50-kDa component of SFD to AP50. Recently, we reported that phosphorylation of 50- and 58-kDa polypeptides was observed only with impure clathrin-coated vesicle pump preparations and that purified pump required SFD for function but lacked any kinase activity (6). (This observation, however, did not exclude the possibility that the 50-kDa component of SFD is AP50, since the primary structure of the latter (19) lacks any known nucleotide binding motif, and its role as a kinase is conjectural.) We now demonstrate that AP50 itself is not a component of the purified clathrin-coated vesicle pump; nor is it required for ATP-driven proton translocation. Through direct protein sequencing and molecular cloning, we show that the 50- and 57-kDa components of SFD are highly related proteins that probably arise through an alternative splicing mechanism. These subunits are termed SFDalpha (57 kDa) and SFDbeta (50 kDa). They share 16% identity to a 54-kDa polypeptide of the yeast vacuolar proton pump encoded by the VMA13 gene (20). No homology, however, exists between these proteins and AP50 or any AP isoforms. These studies demonstrate that SFD, and not AP50, is required for function of the vacuolar-type proton pump of clathrin-coated vesicles.

    EXPERIMENTAL PROCEDURES
Top
Abstract
Introduction
Procedures
Results
Discussion
References

Preparations and Materials-- Isolation of clathrin-coated vesicles from bovine brains (21) and preparations of liposomes from purified lipids (22) were performed as reported. Purification of the proton-translocating ATPase of clathrin-coated vesicles was performed by sequential solubilization with C12E9, hydroxylapatite (HTP) chromatography, (NH4)2SO4 fractionation, and glycerol gradient centrifugations (4); purified H+-ATPase had a specific activity of 14-16 µmol Pi·mg protein-1·min-1. Purified proton pump was depleted of SFD by treatment with Zwittergent 3-16, followed by glycerol gradient centrifugation, as reported (6). Purified AP-2 (µ2) complex from rat brain and chicken anti-AP50 (µ2) IgY were the generous gifts of Dr. Thomas Kirchhausen (Harvard University). Goat anti-chicken IgY antibody was obtained from Pierce, HTP (Bio-GEL HTP) was from Bio-Rad; restriction enzymes, T4 DNA sequencing ligase, and a nick translation kit were from Boehringer Mannheim; DNA sequencing reagents and enzymes and the GeneAmp PCR reagent kit were from Perkin-Elmer; Escherichia coli strains XL1-Blue and BB4 and helper phages R408 were from Stratagene; radioactive reagents were from Amersham Corp.; nitrocellulose membranes for plaque lift were from Millipore Corp.; and chemicals for SDS-PAGE were from Bio-Rad. A bovine brain cDNA library was the generous gift of Dr. Richard Dixon, University of Texas Health Science Center at Houston. The sources of other materials used in this study have been identified previously (3-7).

Protein Sequencing-- About 200 pmol of each of the 50- and 57-kDa components of SFD were separated by SDS-PAGE (12% acrylamide), and proteins were electrophoretically transferred to Immobilon polyvinylidene difluoride filters, from which the 50- and 57-kDa polypeptide bands were excised, and digested with trypsin or LysC in situ (23). Released peptides were separated by reverse phase high performance liquid chromatography using a 2.1 × 150-mm RP300 column from Perkin-Elmer and were subjected to automated Edman degradation using a model 477A amino acid sequencer from Applied Biosystems with the manufacturer's standard program and chemicals.

Synthesis of a DNA Probe by PCR-- To obtain a DNA probe for screening a bovine cDNA library, four rounds of PCR were performed. The first PCR was carried out with a bovine cDNA library as template, using two primers (I, 5'-GCIGCIGCIGT(T/C)TGIGG(T/C)TG(T/C)TC-3'; II, 5'-GTIATIGAICA(G/A)(C/T)TIGGIGGIAA-3') based upon primary peptide sequence. After 30 cycles of PCR, this reaction generated one dominant band of ~500 bp, but sequencing revealed that this arose from primer I annealing to two separate sites in a transcript that did not encode amino acids flanking those used to design primer I. Under the premise that a genuine, relevant PCR product had also been produced (at a much lower copy number than the ~500-bp product), a second PCR reaction was performed. The reaction mix was diluted 100-fold, and 1 µl of the diluted reaction mixture was used as template in this second PCR reaction using primer II and primer III (III, 5'-TATTCCCA(A/G)TT(A/G)TGIACCATIA(A/G)(T/C)TT-3') that was designed according to an expressed sequence tag clone (TO6491) identified by screening expressed sequence tag data bases with peptide sequences obtained from the direct sequencing of the 50-kDa component of SFD. This second round of PCR amplified a 120-bp fragment. To generate a larger DNA fragment suitable for cDNA library screening, the sequence of the 120-bp fragment was used to design two additional primers (IV, 5'-AGACTGGAGTTGTTTACCAAGATA-3'; V, 5'-CTTCTGTACAGCCAGGAGGGCGTT-3'). Primer IV and T3 promotor primer were used in the third round of PCR, using bovine brain cDNA library as template. The reaction mix was diluted 100-fold, and 1 µl of the diluted reaction mixture was used as template in the final round of PCR using primer V and T3 promotor primer. This round of PCR generated an 856-bp fragment that was used to screen the library.

Cloning of cDNAs Encoding SFD of Clathrin-coated Vesicle ATPase-- The 856-bp PCR fragment was labeled with [alpha -32P]dCTP by nick translation and used to screen a bovine brain cDNA library in lambda ZAP, which had been transfected into E. coli strain BB4. Plaques were transferred to nitrocellulose membranes by a double-lift procedure (26). The membranes were then prehybridized for at least 4 h at 60 °C in a solution containing 5 × SSC, 5 × Denhardt's solution, 0.1 mg/ml sheared salmon sperm DNA, and 0.1% SDS. Hybridization was performed at 60 °C overnight with the same solution plus labeled probe, which was added at a concentration of 5-10 × 105 cpm/ml of hybridization solution. Duplicate positive clones were rescreened through one or more cycles until purified plaques were obtained. About 1.3 × 106 independent clones were screened, yielding two independent, full-length clones, SFD-4A and SFD-21.

Based upon the sequences of SFD-4A and SFD-21, two primers were synthesized (VI, 5'-TCCTCCTGCCTCTTCTGGATC-3'; and VII, 5'-GGTCTTCTATCCCAGGTGACT-3') and used for RT-PCR. In brief, 0.1 mg of bovine brain poly(A+) mRNA was reverse transcribed using oligo(dT)16 as primer. SFD coding sequences were then amplified by PCR using primers VI and VII. Two fragments were amplified and were subsequently TA-cloned (24), using an Invitrogen TA cloning kit and the manufacturer's protocol. Four full-length clones, SFD-RT1, -2, -3, and -4, resulted from this approach.

Sequencing of SFD-RT1, -2, -3, and -4 was carried out with ABI PRISMTM Dye Terminator Cycle Sequencing Ready Reaction Kit with Ampli-Taq DNA polymerase and subjected to sequencing analysis using a model 377 ABI PRISM DNA Sequencer. The positive clones were fully sequenced in both orientations using T7 promotor, M13 reverse sequencing primers, and sequence-specific oligonucleotides as primers. DNA and protein data base searches were performed using PC GENE and the Wisconsin Sequence Analysis Package. Clones SFD-RT1, -2, and -3 were identical and were subsequently shown to encode the 50-kDa polypeptide of SFD, which we term SFDbeta . SFD-RT4 encoded the related 57-kDa polypeptide of SFD, which we term SFDalpha .

Antibody Preparation and Western Blot Analysis-- A peptide common to the predicted translations of SFDalpha and SFDbeta (CEMKRSPEEKQEMLQTEGS) and an SFDalpha -specific peptide (CKLRGSGVTAETGTUSSSD) were synthesized, coupled to keyhole limpet hemocyanin, and used for immunization of New Zealand White rabbits (3), yielding Q48 and Q50 antisera, respectively. For Western blot analysis, protein samples were separated by 11% SDS-PAGE and transferred electrophoretically to nitrocellulose paper. Immunodetection was performed using immune serum at a 1:5,000 dilution and an Amersham ECL Western blotting system. Immunoblot protocols using rabbit polyclonal anti-70-kDa subunit antibody (1:5,000 dilution) have been described previously (3). Polyclonal anti-rat AP50 (µ2) IgY from chicken was used at a 1:20,000 dilution, and secondary antibody (goat, anti-chicken IgY) was used at a 1:40,000 dilution. Rabbit polyclonal anti-39-kDa antiserum was generated against recombinant bovine brain 39-kDa polypeptide. This antiserum was used at a 1:5,000 dilution. Protein determination (25) and SDS-PAGE (26) were performed as reported.

Assay of Proton Pumping-- Partially purified proton pump of clathrin-coated vesicles was reconstituted into liposomes prepared from pure lipids by the freeze-thaw, cholate dilution method, as reported (23). Proton pumping was assessed by ATP-dependent quenching of acridine orange in an Aminco DW 2C dual wavelength spectrophotometer as Delta A492-540. Proteoliposomes (1.2 µg of protein) were diluted into 1.5 ml of assay buffer consisting of 150 mM KCl, 2.5 mM MgCl2, 10 mM Na-Tricine (pH 7.0), and 7 µM acridine orange. Reactions were initiated by the addition of 1.3 mM ATP and 1 µM valinomycin and were terminated with the addition of 1 µM bis-(hexafluoroacetonyl)acetone.

    RESULTS
Top
Abstract
Introduction
Procedures
Results
Discussion
References

Fig. 1 illustrates key preparations used to investigate the possible role of AP50 in function of the clathrin-coated vesicle proton pump. SDS-PAGE (panel A), and immunoblot analysis (panel B) were performed using protein amounts chosen to achieve approximately equal staining of polypeptide(s) in the proximity of 50 kDa. As shown in panel B, AP50 is present in clathrin-coated vesicles (lane 1) but was not detected in partially purified pump after HTP chromatography (lane 2), fully purified pump (lane 3), or SFD (lane 4). As positive controls, the antibody is shown to react with the AP50 component of biochemically prepared µ2 complex (lane 5) and recombinant AP50 (lane 6); the latter has a slightly greater Mr than native AP50 because of histidine residues and a factor Xa cleavage site at the amino terminus.


View larger version (58K):
[in this window]
[in a new window]
 
Fig. 1.   Identification of AP50 in clathrin-coated vesicle H+-ATPase preparations. SDS-PAGE, followed by Coomassie Blue staining (panel A) and Western blot analysis (panel B) with an anti-AP50 antibody, were performed as described under "Experimental Procedures." Lane 1, bovine brain clathrin-coated vesicles (3 µg); lane 2, H+-ATPase, partially resolved by HTP chromatography (1.1 µg); lane 3, purified H+-ATPase (2.4 µg); lane 4, purified SFD (0.18 µg); lane 5, purified µ2 complex (1 µg); lane 6, purified recombinant AP50 (0.2 µg).

The results of Fig. 1 indicate that AP50 was not present in our pump preparation after HTP chromatography. To further address this point, the distribution of polypeptides eluted during HTP chromatography was examined by SDS-PAGE, as shown in Fig. 2A. Lanes 3-10 show fractions sequentially eluted by a linear (0-300 mM) NaPi gradient, and lane 11 shows a fraction eluted by a 1 M NaPi wash performed after the gradient. Also illustrated are Western blot analysis performed on the fractions of panel A, using antibodies directed against AP50 (panel B), the 70-kDa proton pump subunit (panel C), and the 39-kDa proton pump subunit (panel D). As shown (panel B), AP50 is not eluted by the standard gradient used to prepare proton pump (lanes 3-10) but was released by a M NaPi step wash (lane 11). In contrast, proton pump components are effectively eluted by the 0-300 mM gradient, as indicated by the simultaneous elutions of the 70-kDa subunit of VC (panel C) and the 39-kDa component of VB (panel D) in lanes 3-7. Notably, neither peripheral (70-kDa) nor membrane-associated (39-kDa) components are eluted by the 1 M NaPi wash (panels C and D, lane 11), demonstrating full separation of the pump components and AP50.


View larger version (77K):
[in this window]
[in a new window]
 
Fig. 2.   AP50 is removed from the clathrin-coated vesicle H+-ATPase by HTP chromatography. HTP chromatography, SDS-PAGE (panel A), and Western blot analysis with anti-AP50 antibody (panel B), anti-70-kDa antibody (panel C), and anti-39-kDa antibody (panel D) were performed as described under "Experimental Procedures." Lane 1, purified H+-ATPase (2.4 µg); lane 2, purified rat µ2 complex (1 µg); lanes 3-10, 20 µl of the HTP chromatography fractions eluted by 0 (lane 3) to 300 mM (lane 10) linear NaPi gradient; lane 11, 20 µl of the HTP chromatography fraction eluted by 1 M NaPi step wash after completion of gradient.

Next, the HTP elution fraction shown in Fig. 2, lane 5, was subjected to glycerol gradient centrifugation. Resultant purified proton pump (Fig. 1A, lane 3) that is devoid of AP50 (Fig. 1B, lane 3) catalyzes a high rate of proton pumping after reconstitution into liposomes prepared from pure lipids (Fig. 3). Taken together, these data indicate that the 50-kDa component of the V-pump of clathrin-coated vesicles is not AP50, claims to the contrary (13, 14) not withstanding.


View larger version (9K):
[in this window]
[in a new window]
 
Fig. 3.   Proton pumping catalyzed by purified proton pump that lacks AP50. ATP generated acridine orange quenching was performed as described under "Experimental Procedures" with 1.2 µg of purified H+-ATPase (shown in Fig. 1, lane 3) reconstituted with purified lipids (16).

To determine the genuine molecular identity of the 50- and 57-kDa components of SFD, these polypeptides were purified and subjected to Edman degradation. Both were blocked at their amino termini, and internal peptides were generated by digestion with trypsin or LysC. After separation by reverse phase high performance liquid chromatography, Edman degradation was performed as described under "Experimental Procedures."

The first indication of similarity of the 57- and 50-kDa polypeptides came from the pattern of peptides generated by trypsin digestion. As shown in Fig. 4, nearly identical elution profiles were obtained for the peptides derived from the 57- and 50-kDa polypeptides (panels A and B, respectively). Shown in Table I are the primary sequences obtained from analysis of tryptic and LysC-derived peptides. Notably, sequences obtained from peaks (T2 and T8) of the 57- and 50-kDa polypeptides were identical. Comparison of these sequences with those of data bases revealed that there was no significant sequence homology except for T1, which showed identity with a human expressed sequence tag (TO6491).


View larger version (17K):
[in this window]
[in a new window]
 
Fig. 4.   High performance liquid chromatography elution profiles of tryptic digests of the 57- and 50-kDa components of SFD. The 57- and 50-kDa subunits of SFD were treated with trypsin, eluted from polyvinylidene difluoride membranes, and subjected to high performance reverse phase liquid chromatography as described elsewhere (24) and under "Experimental Procedures." Panel A, trypsin digest of the 57-kDa component of SFD; panel B, trypsin digest of the 50-kDa component of SFD. Peaks T1, T2, and T8 (panel A) and T2 and T8 (panel B) were subjected to Edman degradation; resulting sequences are listed in Table I.

                              
View this table:
[in this window]
[in a new window]
 
Table I
Sequences of tryptic and Lys C peptides of the 57- and 50-kDa subunits of SFD
After purified 57- and 50-kDa polypeptides of SFD were treated with trypsin or Lys C, peptides were separated by reversed phase high performance liquid chromatography and sequenced, as described under "Experimental Procedures."

As outlined under "Experimental Procedures," the primary sequences of the peptides prepared from the 50- and 57-kDa polypeptides were used to generate an 856-bp PCR product that was then used to probe a bovine brain cDNA library; ultimately, two independent, full-length clones (SFD4 and SDF 21) were isolated. The sequence of SFD21, its predicted amino acid sequence, and alignment with the peptides of T1, T2, T8, and L22 are shown in Fig. 5. The open reading frame encodes a polypeptide composed of 465 amino acids with a predicted molecular mass of 54,187 Da.


View larger version (78K):
[in this window]
[in a new window]
 
Fig. 5.   Nucleotide sequences of SFD-21 and SFD-RT4 and amino acid translations. The full nucleotide sequence of clone SFD-21 is shown; in boldface type is the unique 54-bp insert present in clone SFD-RT4. The locations of SFD-derived peptides T1, T2, T8, and L22 (listed in Table I) are underlined.

Because of the apparent homology found by direct sequencing of the 50- and 57-kDa subunits of SFD, we sought to clone a second cDNA that might encode the other of the two polypeptides. As outlined under "Experimental Procedures," a PCR-based approach ultimately yielded four clones (SFD-RT1, -2, -3, and -4) from bovine brain poly(A)-enriched mRNA. Of these, SFD-RT1, -2, and -3 were identical to one another and to SFD21. SFD-RT4, however, had a sequence identical to SFD21, except that it contained a 54-bp insert, resulting in a protein composed of 483 amino acids with a predicted molecular mass of 55,933 Da. The nucleotide sequence of SFD-RT4 is compared with that of SFD21 in Fig. 5. As shown, these sequences are identical in both the coding and noncoding regions, save the 54-bp insert at nucleotide position 727 of SFD21. The predicted amino acid alignments of SFD-RT4, and SFD21 are of course identical, except for the putative 18-amino acid insert at position 175 (Fig. 6). Based on the differences in mass of the predicated proteins encoded by SFD-RT4 and SFD-21, we presumed that these were equivalent to the 57- and 50-kDa components of SFD, respectively. Provisionally, we assume that these two proteins are isoforms, and we term the product of SFD-RT4 (and the 57-kDa polypeptide) SFDalpha and the product of SFD-21 (and the 50-kDa polypeptide) SFDbeta .3 Data bank searches revealed that SFD polypeptides have 53% (gene T14F9.1) and 40% (gene F52E1.10) identity to probable homologues in Caenorhabditis elegans, 23% identity to a probable homologue (gene SPAC7D4.10) in Schizisaccharomyces pombe, and 16% identity to a 54-kDa subunit of the vacuolar proton pump of S. cerevisiae that is encoded by the VMA13 gene (20); alignments of the predicted amino acid sequences of these proteins with SFDalpha and SFDbeta are shown in Fig. 6.


View larger version (128K):
[in this window]
[in a new window]
 
Fig. 6.   Comparison of amino acid sequences of SFDalpha , SFDbeta , and homologues. Shown is the alignment of predicted amino acid sequences of SFDalpha , SFDbeta , genes T14F9.1 (C. elegans 1) and F52E1.10 (C. elegans 2) of C. elegans, gene SPAC7D4.10 of S. pombe, and gene VMA13 of S. cerevisiae. Residues identical to those of SFDalpha and SFDbeta have a black background residues similar are noted by a gray background.

To further establish the relationship of these two polypeptides to SFD, we generated antibodies to synthetic peptides predicted from the translated nucleotide sequences of the 57- and 50-kDa components of SFD. The first of these, Q48, was generated against an epitope common to SFDalpha and -beta , while the second, Q50, was generated against the predicted unique 18-amino acid insert present in SFDalpha . Shown in Fig. 7 are the results of Western blot analysis using these antibodies. As shown, antiserum directed against the common epitope (Q48) reacts with both the 57- and 50-kDa subunits present in holoenzyme (panel B, lane 1) and in purified SFD (panel B, lane 3). In contrast, antibody Q50, directed against the unique 18-amino acid insert of SFDalpha , reacts only with the 57-kDa component of purified pump (panel C, lane 1) and SFD (panel C, lane 3). Neither antiserum reacted with V-pump that had been selectively depleted of SFD (panels B and C, lane 2).


View larger version (29K):
[in this window]
[in a new window]
 
Fig. 7.   Immunoblot analysis of SFDalpha and SFDbeta . SDS-PAGE (panel A) and Western blot analysis using Q48 (panel B) or Q50 (panel C) antiserum were performed as described under "Experimental Procedures." Lane 1, purified proton pump (4 µg); lane 2, purified proton pump depleted of SFD (4 µg); lane 3, purified SFD (400 ng).

    DISCUSSION
Top
Abstract
Introduction
Procedures
Results
Discussion
References

The results of this study demonstrate that the clathrin-coated vesicle proton pump is highly active in the absence of AP50 (Fig. 3) and that SFDalpha and -beta are distinct from AP50. It is important to note that these conclusions are in part based on the use of the identical antibody used in the previous reports (13), indicating that AP50 was required for function of the clathrin-coated vesicle proton pump. We believe differences between our results and those published previously are in part due to variations in the methods of preparation of active H+-ATPase from clathrin-coated vesicles that were employed in the two studies.

Purification of the clathrin-coated vesicle proton pump, in our hands, is achieved by an extended protocol consisting of solubilization of stripped clathrin-coated vesicle membranes with C12E9, followed by centrifugation at 150,000 × g for 60 min, HTP chromatography, (NH4)2SO4 fractionation, and glycerol gradient centrifugation. Enzyme, thus prepared, has a specific activity of 14-16 µmol Pi·mg protein-1·min-1 and is dependent upon phospholipid (optimally, phosphatidylserine) for activation of ATPase activity, and liposomes for reconstitution of proton pump activity (4). In contrast, reports of the role of AP50 in the function of clathrin-coated vesicle proton pump were based on studies of enzyme prepared by an abbreviated version of our protocol. The isolation protocol of these studies (13, 14) consisted of treating stripped vesicles with C12E9, followed by centrifugation at 100,000 × g, and glycerol gradient centrifugation. The resultant preparation has a specific activity of 6 µmol Pi·mg protein-1·min-1. It is thus possible that the preparation of proton pump used by others was contaminated with AP50 and that their attempts to directly sequence the 50-kDa component yielded residues from the amino terminus of AP50, but not SFDbeta , which was not susceptible to amino terminus sequencing in our hands. Other claims regarding the role of AP50 in pump structure and function, such as the reported stoichiometry of about 1 mol of AP50/mol of proton pump (13, 14) remain inexplicable. In particular, the report that the AP2 complex is itself fundamentally required for both pump activity and the reassembly of dissociated proton pump components (14) is in direct conflict with the previous biochemical (6) and current molecular characterizations of SFD from our laboratory. Irrespective of these points, it is clear that inclusion of HTP chromatography as a pump purification step results in separation of AP50 from fully functional enzyme (see above); thus, we find no support for the notion (14) that AP50 is required for acidification catalyzed by the proton pump of clathrin-coated vesicles.

Molecular cloning of the components of SFDalpha and -beta demonstrates that they differ only by a 54-bp "insert" present in the former. Because of nucleotide identity at all other positions, including noncoding regions at the 3'- and 5'-ends of the clones, it is most likely that this difference in sequences is due to alternative splicing, as has been shown for a number of V-pump subunits. It is further possible that SFDalpha and SFDbeta are isoforms. Biochemical studies will be required to determine if there are requirements for both components in the function of a single pump or whether a single form is sufficient for function.

Sequence homology of SFDalpha and -beta with the VMA13 product (20) underscores the apparent similarity in function of these components in V-pumps from bovine brain and yeast, respectively. Specifically, SFD was shown to activate Mg-ATPase activity of the V-pump of clathrin-coated vesicles and to functionally couple ATP hydrolysis to proton flow. Also, V-pump selectively depleted of SFD remains intact but cannot support proton pumping (6). These characteristics are highly similar to those observed in VMA13 knock-out experiments, where it was found that the V-pump of yeast vacuoles, although assembled, was inactive with regard to ATPase and proton pumping activities (20).

Site-specific regulation of V-pump activity is an issue of broad interest that relates to the maintenance and generation of different pH gradients in organelles of the constitutive trafficking pathways and to the role that this interorganelle pH gradient plays in targeting nascent proteins to their ultimate cellular destinations. Although it is possible that AP50 and V-type proton pumps interact to produce some currently undefined function, our data refute the notion that AP50 is an organelle-specific regulator of V-pump function and specifically demonstrate that AP50 is not required for pump activity. We thus are focused on determining the molecular characteristics of SFD and its role in the function of V-type proton pumps.

    FOOTNOTES

* This work was supported by National Institutes of Health Grant DK-33627.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

The nucleotide sequence(s) reported in this paper has been submitted to the GenBankTM/EMBL Data Bank with accession number(s) AF041337 and AF041338.

§ To whom correspondence should be addressed: Div. of Molecular Transport, Dept. of Internal Medicine, University of Texas Southwestern Medical Center, 5323 Harry Hines Blvd., Dallas, TX 75235-9121. Tel.: 214-648-7606; Fax: 214-648-7542.

1 The abbreviations used are: VB, the bafilomycin-sensitive proton channel of V-type proton pumps; VC, the peripheral, catalytic sector of V-type proton pumps; bp, base pair; C12E9, polyoxyethylene 9-lauryl ether; HTP, hydroxylapatite; PAGE, polyacrylamide gel electrophoresis; SFD (sub-fifty-eight-kDa dimer), the 50-57-kDa polypeptide heterodimer required for function of the vacuolar proton pump of clathrin-coated vesicles; PCR, polymerase chain reaction; Tricine, N-[2-hydroxy-1,1-bis(hydroxymethyl)ethyl]glycine.

2 Acidification activity in clathrin-coated vesicle preparations probably arises from Golgi-derived clathrin-coated vesicles, which are associated with AP-1 (17, 18).

3 The predicted masses of SFDalpha and SFDbeta are in approximate accord with molecular radii based upon electrophoretic mobility. At present, we have no evidence of postranslational modification of either species.

    REFERENCES
Top
Abstract
Introduction
Procedures
Results
Discussion
References

  1. Stone, D. K., and Xie, X.-S. (1988) Kidney Int. 33, 403-413
  2. Rea, P. A., Kim, Y., Sarafian, V., Poole, R. J., Davies, J. M., Sanders, D. (1992) Trends Biochem. Sci. 17, 348-352[CrossRef][Medline] [Order article via Infotrieve]
  3. Mattsson, J. P., Schlesinger, P. H., Keeling, D. J., Teitelbaum, S. L., Stone, D. K., Xie, X.-S. (1994) J. Biol. Chem. 269, 24979-24982[Abstract/Free Full Text]
  4. Xie, X.-S., and Stone, D. K. (1986) J. Biol. Chem. 261, 2492-2495[Abstract/Free Full Text]
  5. Crider, B. P., Xie, X.-S., and Stone, D. K. (1994) J. Biol. Chem. 269, 17379-17381[Abstract/Free Full Text]
  6. Xie, X.-S., Crider, B. P., Ma, Y.-M., and Stone, D. K. (1994) J. Biol. Chem. 269, 25809-25815[Abstract/Free Full Text]
  7. Xie, X.-S., and Stone, D. K. (1988) J. Biol. Chem. 263, 9859-9867[Abstract/Free Full Text]
  8. Kane, P. M., and Stevens, T. H. (1992) J. Bioenerg. Biomembr. 24, 383-393[Medline] [Order article via Infotrieve]
  9. Bowman, B. J., Vasques-Laslop, N., and Bowman, E. J. (1992) J. Bioenerg. Biomembr. 24, 361-370[Medline] [Order article via Infotrieve]
  10. Moriyama, Y., and Nelson, N. (1989) J. Biol. Chem. 264, 3577-3582[Abstract/Free Full Text]
  11. Bowman, B. J., Allen, R., Wechser, M. A., Bowman, E. J. (1988) J. Biol. Chem. 263, 14002-14007[Abstract/Free Full Text]
  12. Graf, R., Lepier, A., Harvey, W. R., Weiczorek, H. (1994) J. Biol. Chem. 269, 3767-3774[Abstract/Free Full Text]
  13. Meyers, M., and Forgac, M. (1993) J. Biol. Chem. 268, 9184-9186[Abstract/Free Full Text]
  14. Liu, Q., Feng, Y., and Forgac, M. (1994) J. Biol. Chem. 269, 31592-31597[Abstract/Free Full Text]
  15. Keen, J. H. (1990) Annu. Rev. Biochem. 59, 415-438[CrossRef][Medline] [Order article via Infotrieve]
  16. Phan, H. L., Finlay, J. A., Chu, D. S., Tan, P. K., Kirchhausen, T., Payne, G. S. (1994) EMBO J. 13, 1706-1717[Abstract]
  17. Fuchs, R., Ellinger, A., Pavelka, M., Mellman, I., and Klapper, H. (1994) Proc. Natl. Acad. Sci. U. S. A. 91, 4811-4815[Abstract]
  18. Anderson, R. G. W., and Orci, L. (1988) J. Cell Biol. 106, 529-543
  19. Thurrieau, C., Brosius, J., Burne, C., Jolles, P., Keen, J. H., Madeleine, R. J., Chow, E. P., Ramachandran, K. L., Kirchhausen, T. (1988) DNA 7, 663-669[Medline] [Order article via Infotrieve]
  20. Ho, M. N., Hirata, R., Umemoto, N., Ohya, Y., Takatsuki, A., Stevens, T. H., Anraku, Y. (1993) J. Biol. Chem. 268, 18286-18292[Abstract/Free Full Text]
  21. Nandi, P. K., Irace, G., Van Jaarsveld, P. O., Lippoldt, R. E., Edelhoch, H. (1982) Proc. Natl. Acad. Sci. U. S. A. 79, 5881-5885[Abstract]
  22. Xie, X.-S., and Stone, D. K. (1986) Proc. Natl. Acad. Sci. U. S. A. 83, 8913-8917[Abstract]
  23. Fernandez, J., Demlott, M., Aatherton, D., and Mische, S. M. (1992) Anal. Biochem. 201, 255-264[Medline] [Order article via Infotrieve]
  24. Clark, J. M. (1988) Nucleic Acids Res. 16, 9677-9686[Abstract]
  25. Schaffner, W., and Weissmann, C. (1973) Anal. Biochem. 56, 502-508[Medline] [Order article via Infotrieve]
  26. Laemmli, U. K. (1970) Nature 227, 680-685[Medline] [Order article via Infotrieve]


Copyright © 1998 by The American Society for Biochemistry and Molecular Biology, Inc.